Filtered By:
Condition: Chronic Pain
Education: Learning

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 62 results found since Jan 2013.

Should You Take Aspirin Every Day? Here ’s What the Science Says
Aspirin is best known as an over-the-counter painkiller. But acetylsalicylic acid, as it’s called chemically, has many other health benefits, as well as side effects, in the body that have only become clear in recent years. Here’s what the latest science says about the health benefits and side effects of aspirin, as well as which conditions it may treat and those it doesn’t appear to improve. (If you are taking aspirin for any reason other than for periodic pain relief, it’s best to consult with your doctor to confirm whether the benefits outweigh the risks in your particular case.) How aspirin affe...
Source: TIME: Health - November 8, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthytime Source Type: news

10 New Year ’s Resolutions Doctors Actually Want You to Make
Each year, Americans’ most popular New Year’s resolutions are more or less the same: get healthy, get organized, save money. But doctors at the American Medical Association (AMA) have some more specific thoughts in mind for 2019. The AMA this week released a list of 10 wellness-focused resolutions that could “help Americans make the most impactful, long-lasting improvements to their health in 2019.” Here’s what they are — and how to make them happen. Learn your risk for type 2 diabetes Diabetes is one of the most common chronic health conditions in the U.S., affecting an estimated 30 mil...
Source: TIME: Health - December 21, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime Holidays 2018 public health Source Type: news

10 New Year's Resolutions Doctors Actually Want You to Make
Each year, Americans’ most popular New Year’s resolutions are more or less the same: get healthy, get organized, save money. But doctors at the American Medical Association (AMA) have some more specific thoughts in mind for 2019. The AMA this week released a list of 10 wellness-focused resolutions that could “help Americans make the most impactful, long-lasting improvements to their health in 2019.” Here’s what they are — and how to make them happen. Learn your risk for type 2 diabetes Diabetes is one of the most common chronic health conditions in the U.S., affecting an estimated 30 mil...
Source: TIME: Health - December 21, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime Holidays 2018 public health Source Type: news

Transcranial Direct Current Stimulation Use in Warfighting: Benefits, Risks, and Future Prospects
Conclusion The aim of this paper was to examine whether military tDCS use can be efficacious and ethical in military settings. Our assessment is that tDCS offers a number of cognitive, motor, and perceptual enhancement opportunities which could provide value in military situations like training and operations. There is potential scope for use in a number of key areas that directly affect practical battlefield advantage and survivability, such as deceptive capabilities, risk-taking, threat detection, perception, and physiological improvement. Additionally, tDCS has the potential to improve command and control decision maki...
Source: Frontiers in Human Neuroscience - April 17, 2019 Category: Neuroscience Source Type: research

Feasibility of home-based, self-applied transcranial direct current stimulation to enhance motor learning in middle-aged and older adults
We read with great interest the recent letter sent to you by McConnell and colleagues [1], in which they discuss one of the first applications of truly independent home-based electrical brain stimulation, applied following safety recommendations. Transcranial direct-current stimulation (tDCS) is a non-invasive brain stimulation technique capable of modulating cortical excitability beyond the stimulation period [2,3]. tDCS presents interesting options as a therapeutic intervention in multiple neurological disorders, such as stroke, depression, chronic pain, schizophrenia, and Alzheimer ’s and Parkinson’s disease [4,5].
Source: BRAIN STIMULATION: Basic, Translational, and Clinical Research in Neuromodulation - September 23, 2019 Category: Neurology Authors: Pablo Maceira-Elvira, Traian Popa, Anne-Christine Schmid, Friedhelm C. Hummel Source Type: research

Lysophosphatidic Acid Receptor Signaling Underlying Chronic Pain and Neuroprotective Mechanisms through Prothymosin α.
Abstract For my Ph.D. research topic, I isolated endogenous morphine-like analgesic dipeptide, kyotorphin, which mediates Met-enkephalin release, and discovered kyotorphin synthetase, a putative receptor and antagonist. Furthermore, I succeeded in purifying μ-opioid receptor and functional reconstitution with purified G proteins. After receiving my full professor position at Nagasaki University in 1996, I worked on two topics of research, molecular mechanisms of chronic pain through lysophosphatidic acid (LPA) and identification and characterization of neuroprotective protein, prothymosin α. In a series of studi...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - November 8, 2019 Category: Drugs & Pharmacology Authors: Ueda H Tags: Yakugaku Zasshi Source Type: research

What Are Some Risk Factors for Cerebral Palsy?
Discussion The term, cerebral palsy, or CP has gone through many iterations with the first description in 1861 by W.J. Little who described it as “The condition of spastic rigidity of the limbs of newborn children.” The most recent definition is from Rosenbaun et al. in 2007 which states it is “a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cog...
Source: PediatricEducation.org - March 9, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Characteristic of Clinical Studies on Baduanjin during 2000-2019: A Comprehensive Review.
Authors: Zhou J, Yu Y, Cao B, Li X, Wu M, Wen T, Xiong Y, Jia J, Zhao Y Abstract To date, a growing number of clinical studies have demonstrated the safety and health benefits from Baduanjin intervention. Based on this, our objective is to systematically retrieve and summarize the clinical studies on Baduanjin, with a view to providing more evidence-based evidence in support of the application of Baduanjin for healthcare, and to identify the shortcomings of existing research and provide feasibility suggest for further clinical research. Both four English language and four Chinese language electronic databases were ...
Source: Evidence-based Complementary and Alternative Medicine - November 6, 2020 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK/NF- κB pathway in neuropathic pain mice
Neurobiol Learn Mem. 2021 May 17:107463. doi: 10.1016/j.nlm.2021.107463. Online ahead of print.ABSTRACTGrowing evidences indicate that neuropathic pain is frequently accompanied with cognitive impairments, which aggravate the decrease in the quality of life of chronic pain patients. Furthermore, it has been shown that the activation of Glucagon-like-peptide-1receptor (GLP-1R) improved memory deficit in multiple diseases, including Alzheimer's disease (AD), stroke. However, whether GLP-1R activation could improve memory impairment induced by neuropathic pain and the mechanisms underlying the effect of the activation of GLP-...
Source: Neurobiology of Learning and Memory - May 20, 2021 Category: Neurology Authors: Long-Qing Zhang Wen Zhang Ting Li Ting Yang Xiaoman Yuan Yaqun Zhou Qian Zou Hui Yang Feng Gao YuKe Tian Wei Mei Xue-Bi Tian Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news